Molecular Pharmacology
A section of International Journal of Molecular Sciences (ISSN 1422-0067).
Section Information
This section of the International Journal of Molecular Sciences (IJMS) aims to rapidly publish novel data concerning molecular pharmacology. Pharmacology is a discipline which deals with the interaction of a drug of natural, semisynthetic or fully (bio)synthetic origin with the human or animal organism. Thus, it is positioned at the interface of pharmacy/chemistry and physiology/pathophysiology in their broadest sense. It operates at various organizational levels, such as the molecular, subcellular, cellular, organ, and systemic platforms. Molecular pharmacology investigates the molecular mode of action of drugs, among others using genetic and molecular biology methods, and in consequence, it is one of the most rapidly developing fields of pharmacology. We encourage submission of manuscripts that report significant advances on the molecular level in drug research but especially appreciate submissions which, in addition, follow up on the consequences of molecular changes on higher levels of organization.
Keywords
biochemical pharmacology; biomarkers; biosynthetics; chromosome; DNA structure; epigenetics; genetics; genomics; histology; individually tailored therapy; medicinal chemistry; medicine; membrane proteins; membrane transport; molecular biology; molecular pharmacology; pathophysiology; pharmacy; physiology; population genetics; proteomics; RNA structure; signal transduction; stem cells; transcriptional analyses; transgenic techniques; translational analyses
Editorial Board
Topical Advisory Panel
Special Issues
Following special issues within this section are currently open for submissions:
- Bridging the Gap between the Clinical and Regulatory Use of Plasma Rich in Growth Factors. Where Are We? (Deadline: 31 May 2022)
- New Drugs for Breast Cancer Treatment (Deadline: 31 May 2022)
- Recent Advances in B Cells: Signal Transduction and Therapeutic Potential (Deadline: 31 May 2022)
- Pharmacology of Hormones, Peptides and Growth Factors in Systemic Cross-Talk (Deadline: 31 May 2022)
- Cancer Cell Models for the Development of Anti-cancer Drugs (Deadline: 31 May 2022)
- Pharmacological Strategies for Neuroinflammation in Brain Injury (Deadline: 31 May 2022)
- Application of Chitosan in Drug Delivery (Deadline: 31 May 2022)
- Molecular Insight into Tubular Mechanism for Handling Chronic Kidney Disease (Deadline: 31 May 2022)
- Pharmacological Strategies for Diabetes Treatment (Deadline: 31 May 2022)
- Pharmacology in Pain Management (Deadline: 31 May 2022)
- Cell Therapy Approaches for Diabetes (Deadline: 24 June 2022)
- Natural Bioactive Compounds for Human Health (Deadline: 27 June 2022)
- Oligonucleotide, Therapy, and Applications 2.0 (Deadline: 29 June 2022)
- Molecular Mechanisms of Drug Resistance in Cancer: From Chemotherapy to Immunotherapy (Deadline: 30 June 2022)
- Antineoplastic Drugs-Induced Cardiotoxicities: Molecular Insights and Novel Opportunities for Precise Drug Delivery (Deadline: 30 June 2022)
- New Frontiers in Placental Development and Fetal Growth: Focus on Molecular Regulatory Mechanisms and Pharmacology (Deadline: 30 June 2022)
- Strategies to Improve Antineoplastic Activity of Drugs in Cancer Progression (Deadline: 30 June 2022)
- Advances in Photopharmacology (Deadline: 30 June 2022)
- The Collagen Connection (Deadline: 30 June 2022)
- ADME of Novel Modalities Synopsis (Deadline: 30 June 2022)
- ncRNAS in Therapeutics (Deadline: 30 June 2022)
- Effects of Drugs of Abuse on the Blood-Brain Barrier (Deadline: 30 June 2022)
- Exposure to Phytocannabinoids: Exploring Central Effects and Toxicity (Deadline: 30 June 2022)
- Stem Cell Biology of Myeloid Neoplasms 2.0 (Deadline: 30 June 2022)
- Harnessing a Secret Killer: Inflammation and Its Ultimate Resolution (Deadline: 30 June 2022)
- Nanotechnology-Based Drug Delivery Systems for Cancer Therapy (Deadline: 30 June 2022)
- Pharmacotherapy of the Lipid-Lowering Drugs: Update on Efficacy and Risk (Deadline: 30 June 2022)
- New Perspectives on Drugs Targeting Lipid-Transfer Proteins (Deadline: 30 June 2022)
- Impact of Natural Products on Glycation Linked Metabolic Disease (Deadline: 30 June 2022)
- Novel Therapeutic Approaches in Neuroscience Research (Deadline: 30 June 2022)
- Tissue Injury-Initiated Transcriptional Programs and Therapeutic Targets in the Nociceptive System (Deadline: 30 June 2022)
- Recent Advances of Natural Chemical as Kinase Inhibitor (Deadline: 30 June 2022)
- Hemichannel and Neuropsychiatric Disorders (Deadline: 30 June 2022)
- Overcoming Biological Barriers: Importance of Membrane Transporters in Homeostasis, Disease, and Disease Treatment (Deadline: 1 July 2022)
- Tryptophan in Nutrition and Health 2.0 (Deadline: 20 July 2022)
- Cardiovascular Risk in Diabetes Mellitus: Mechanisms, Drugs, and Other Therapies (Deadline: 30 July 2022)
- TRP Channel (Deadline: 31 July 2022)
- Protein–Protein Interactions, Latest Drug Development Advances (Deadline: 31 July 2022)
- hiPSC-Derived Cells as Models for Drug Discovery 2.0 (Deadline: 31 July 2022)
- Novel Therapeutic Approaches for Endothelial Dysfunction (Deadline: 31 July 2022)
- The Pharmacology of Neurotransmission: Focus on Synaptic Alterations during Neurodegeneration and Treatments 2.0 (Deadline: 31 July 2022)
- Pharmacology of Potassium Channels (Deadline: 31 July 2022)
- SGLT2 Inhibitors: Emerging "Magic Bullets" beyond Glycemic Control (Volume 2) (Deadline: 31 July 2022)
- Nanoformulations and Nano Drug Delivery (Deadline: 31 July 2022)
- Pharmacogenetics and Personalized Medicine 3.0 (Deadline: 31 July 2022)
- State-of-the-Art Molecular Pharmacology in Brazil (Deadline: 31 July 2022)
- Micro and Nanosystems for Drug Delivery (Deadline: 31 July 2022)
- Cellular Senescence and the Inflammatory Response in Health and Disease (Deadline: 31 July 2022)
- Molecular Pharmacology in Diabetes (Deadline: 31 July 2022)
- Natural Product-Derived Compounds for Targeting Multidrug Resistance in Cancer and Microorganisms (Deadline: 1 August 2022)
- Epilepsy Research and Antiepileptic Drugs (Deadline: 24 August 2022)
- Drug Resistance in Cancer: Molecular Mechanisms and Tackling Strategies (Deadline: 28 August 2022)
- Latest Advances in Nanomedicine Strategies for Different Diseases (Deadline: 31 August 2022)
- Natural and Synthetic Compounds for Management, Prevention and Treatment of Obesity 2.0 (Deadline: 31 August 2022)
- Recent Applications of PLGA-Based Nanoparticles in Drug Delivery (Deadline: 31 August 2022)
- Novel Strategies in the Development of New Therapies, Drug Substances and Drug Carriers 2.0 (Deadline: 31 August 2022)
- The Development of New Drugs for Alzheimer’s Disease (Deadline: 31 August 2022)
- Advances in Alzheimer’s Disease Drug Research and Development (Deadline: 31 August 2022)
- Molecular Effects of Stress in the Brain: Looking for New Drug Targets for Psychopathologies (Deadline: 31 August 2022)
- Recent Advances in Antidepressants and Mood-Stabilizing Drugs (Deadline: 31 August 2022)
- Natural Product-Based Drug Discovery for COVID-19 Disease (Deadline: 31 August 2022)
- Molecular and Cellular Mechanisms of Epilepsy (Deadline: 31 August 2022)
- Advances in Molecular Activity of Potential Drugs 2.0 (Deadline: 31 August 2022)
- Targeted Therapy of Hematological Malignancies (Deadline: 31 August 2022)
- The Discovery and Development of Cisplatin (Deadline: 30 September 2022)
- Pharmacogenomics 2.0 (Deadline: 30 September 2022)
- Advances in Diabetes, Complication and Metabolic Syndrome (Deadline: 30 September 2022)
- Recent Advances in Antibody Therapeutics 2.0 (Deadline: 30 September 2022)
- Advances in Epilepsy and Antiepileptic Drugs 2.0 (Deadline: 30 September 2022)
- Regulation and Treatment of Esophageal Mucosa Disorders: Novel Factors, Mechanisms, and Pharmaceutical Targets (Deadline: 30 September 2022)
- Antiviral Drugs and Virus Infection (Deadline: 30 September 2022)
- The Interaction between Cell and Virus (Deadline: 30 September 2022)
- Bioactive Molecules and Health (Deadline: 30 September 2022)
- Advances in the Pharmacology of Monoamines, Histamines and Their Inhibitors (Deadline: 30 September 2022)
- Exploiting the Multitarget and Repositioned Drugs Approach 2.0 (Deadline: 30 September 2022)
- Novel Therapeutic Targets for Pulmonary Arterial Hypertension (Deadline: 30 September 2022)
- Hydrogen Sulfide (H2S)-Donor Molecules: Chemical, Biological, and Therapeutical Tools (Deadline: 15 October 2022)
- Recent Advances of Novel Pharmaceutical Designs for Anti-cancer Therapies (Deadline: 31 October 2022)
- Recent Advances of Site-Specific Antibody Drug Conjugations for Clinical Application (Deadline: 31 October 2022)
- Neuropharmacology and Neurodegenerative Diseases (Deadline: 31 October 2022)
- Is Vesicular Therapy the Newcomer That Matters for the Medicine of Tomorrow? (Deadline: 31 October 2022)
- Targeting Human Inflammatory Skin Diseases with Natural Products: Exploring Potential Mechanisms and Regulatory Pathways (Deadline: 31 October 2022)
- Progress of Tumor-Targeted Drugs (Deadline: 31 October 2022)
- Pharmacological Strategies and Molecular Mechanisms Associated with the Novel Nephroprotective Treatments (Deadline: 31 October 2022)
- Novel PET Radiopharmaceuticals: Molecular Probes for Personalized Imaging (Deadline: 10 November 2022)
- Progress in Targeted Therapeutics of Ovarian Cancer (Deadline: 30 November 2022)
- Advances in the Design of Hydrogels for Therapeutic Agent and Cell Delivery (Deadline: 30 November 2022)
- Recent Advances of Bioactive Compounds in Pharmaceutical Designs for Treating Skin Diseases (Deadline: 30 November 2022)
- Biological Properties of Medicinal Plants (Deadline: 30 November 2022)
- Natural Compounds in Cancer Therapy and Prevention (Deadline: 30 November 2022)
- COVID-19 Innovative Drug Treatments: Looking for the Magic Cure to End the Pandemic (Deadline: 30 November 2022)
- Advanced Antiviral and Antimicrobial Drug Discovery (Deadline: 10 December 2022)
- Recent Advances: Heterocycles in Drugs and Drug Discovery (Deadline: 30 December 2022)
- Multi-Target Directed Ligands in Drug Development (Deadline: 31 December 2022)
- Personalized Drug Therapy: From Therapeutic Drug Monitoring to Clinical Outcome (Deadline: 31 December 2022)
- Small Interfering RNAs, Antisense Drugs and Therapeutic Oligonucleotide Analogues (Deadline: 31 December 2022)
- Innovative Radiation Therapies (Deadline: 31 December 2022)
- Advances in Integration of Pharmacogenetics into Practice (Deadline: 31 December 2022)
- Pharmacological Insights of Venoms (Deadline: 31 December 2022)
Topical Collections
Following topical collections within this section are currently open for submissions:
- Advances in Medicinal Chemistry
- Feature Papers in Molecular Pharmacology
- Orphan Drugs
- Pharmacology of Neurodegenerative Diseases
- Sphingolipid Signaling in Health and Disease
- State-of-the-Art Molecular Pharmacology in France
- State-of-the-Art Molecular Pharmacology in Italy
- State-of-the-Art Molecular Pharmacology in Japan
- State-of-the-Art Molecular Pharmacology in Netherlands
- State-of-the-Art Molecular Pharmacology in Spain
- State-of-the-Art Molecular Pharmacology in USA
